News  

100,000 women die of cervical cancer yearly in Nigeria, says expert

By Charles Coffie Gyamfi, Abeokuta   |   12 November 2015   |   3:51 am  
PHOTO: isabellaspace.deviantart.com

PHOTO: isabellaspace.deviantart.com

No fewer than 100,000 Nigerian women die of cervical cancer yearly in the country.

This was disclosed by a former Advisor to the World Health Organisation (WHO), Professor Oladapo Walker at the Annual General Meeting (AGM) of the Association of Resident Doctors (ARD) holding at Babcock University Teaching Hospital chapter, Ilisan Remo, Ogun State.

His words, “I can tell you for sure that every year about a 100,000 women in Nigeria die of cervical cancer. Globally about a million women have the disease. With the population of Nigeria, saying that about hundred thousand women have the disease every year is a gross under-estimation”.



  • Terry Lynch

    Resolution Biomedical Inc. (RBI) based in Tustin, California is proudly collaborating with Dr. Augustin Iluore from Los Angeles (Ascendia Cytology) USA to introduce our affordable Pap test kits into the Nigerian medical marketplace by
    early 2016. The ClearPrep® liquid-based cytology system (LBC) does not require expensive equipment and can be utilized by any size medical laboratory, as a testing service for doctor’s offices or clinic setting as a low cost, effective and highly accurate for early detection for cervical cancer.
    This simple methodology uses a non-invasive cervical collection brush or any other standard device to collect sample cells, that are then transferred into our patented collection vial containing 20ml of preservative solution to keep the sample pristine. The sample is then shipped to the lab for processing. The LBC method is an improvement over the old “smeared glass” or conventional collection method that does not allow for co-testing HPV* or other STD’s from the same sample. (*HPV strains 16, 18 are known as the major cause of cervical cancer in women)
    Cervical cancer if caught early, can be effectively dealt with in most cases, which is why this deadly disease is not prevalent in the Western World, that routinely offer a standard Pap test every 3 – 5 years. RBI is proud to be associated with such a noble cause and we hope that the medical communities in many of the developing countries will start to adopt the same regiment to save lives. The latest WHO report for worldwide cervical cancer deaths is staggering.
    This should not be an acceptable situation, when a simple low cost Pap screen test for under US $3.00 is not made a major priority around the world. We are actively working with medical distribution partners in over 35 countries to spread the word and save lives. For more information please visit http://www.clearprepcytology.com

You may also like